Connection

MING HU to Humans

This is a "connection" page, showing publications MING HU has written about Humans.
Connection Strength

0.431
  1. Bioavailability and pharmacokinetics of genistein: mechanistic studies on its ADME. Anticancer Agents Med Chem. 2012 Dec; 12(10):1264-80.
    View in: PubMed
    Score: 0.011
  2. A new strategy to rapidly evaluate kinetics of glucuronide efflux by breast cancer resistance protein (BCRP/ABCG2). Pharm Res. 2012 Nov; 29(11):3199-208.
    View in: PubMed
    Score: 0.011
  3. Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein. Drug Metab Dispos. 2012 Oct; 40(10):1883-93.
    View in: PubMed
    Score: 0.011
  4. Accurate prediction of glucuronidation of structurally diverse phenolics by human UGT1A9 using combined experimental and in silico approaches. Pharm Res. 2012 Jun; 29(6):1544-61.
    View in: PubMed
    Score: 0.011
  5. Inhibition of P-glycoprotein leads to improved oral bioavailability of compound K, an anticancer metabolite of red ginseng extract produced by gut microflora. Drug Metab Dispos. 2012 Aug; 40(8):1538-44.
    View in: PubMed
    Score: 0.011
  6. SULT1A3-mediated regiospecific 7-O-sulfation of flavonoids in Caco-2 cells can be explained by the relevant molecular docking studies. Mol Pharm. 2012 Apr 02; 9(4):862-73.
    View in: PubMed
    Score: 0.011
  7. Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. Drug Metab Rev. 2012 May; 44(2):192-208.
    View in: PubMed
    Score: 0.011
  8. UDP-glucuronosyltransferase (UGT) 1A9-overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP. Drug Metab Dispos. 2012 Feb; 40(2):336-45.
    View in: PubMed
    Score: 0.011
  9. Regioselective sulfation and glucuronidation of phenolics: insights into the structural basis. Curr Drug Metab. 2011 Nov; 12(9):900-16.
    View in: PubMed
    Score: 0.011
  10. Evaluation of 3,3',4'-trihydroxyflavone and 3,6,4'-trihydroxyflavone (4'-O-glucuronidation) as the in vitro functional markers for hepatic UGT1A1. Mol Pharm. 2011 Dec 05; 8(6):2379-89.
    View in: PubMed
    Score: 0.011
  11. Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. Drug Metab Dispos. 2011 Oct; 39(10):1866-72.
    View in: PubMed
    Score: 0.010
  12. Uridine diphosphate glucuronosyltransferase isoform-dependent regiospecificity of glucuronidation of flavonoids. J Agric Food Chem. 2011 Jul 13; 59(13):7452-64.
    View in: PubMed
    Score: 0.010
  13. First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. J Pharm Sci. 2011 Sep; 100(9):3655-81.
    View in: PubMed
    Score: 0.010
  14. Regioselective glucuronidation of flavonols by six human UGT1A isoforms. Pharm Res. 2011 Aug; 28(8):1905-18.
    View in: PubMed
    Score: 0.010
  15. Validated LC-MS/MS method for the determination of maackiain and its sulfate and glucuronide in blood: application to pharmacokinetic and disposition studies. J Pharm Biomed Anal. 2011 May 15; 55(2):288-93.
    View in: PubMed
    Score: 0.010
  16. Three-dimensional quantitative structure-activity relationship studies on UGT1A9-mediated 3-O-glucuronidation of natural flavonols using a pharmacophore-based comparative molecular field analysis model. J Pharmacol Exp Ther. 2011 Feb; 336(2):403-13.
    View in: PubMed
    Score: 0.010
  17. Highly variable contents of phenolics in St. John's Wort products affect their transport in the human intestinal Caco-2 cell model: pharmaceutical and biopharmaceutical rationale for product standardization. J Agric Food Chem. 2010 Jun 09; 58(11):6650-9.
    View in: PubMed
    Score: 0.010
  18. Use of glucuronidation fingerprinting to describe and predict mono- and dihydroxyflavone metabolism by recombinant UGT isoforms and human intestinal and liver microsomes. Mol Pharm. 2010 Jun 07; 7(3):664-79.
    View in: PubMed
    Score: 0.010
  19. Bioavailability challenges associated with development of anti-cancer phenolics. Mini Rev Med Chem. 2010 Jun; 10(6):550-67.
    View in: PubMed
    Score: 0.010
  20. Use of isoform-specific UGT metabolism to determine and describe rates and profiles of glucuronidation of wogonin and oroxylin A by human liver and intestinal microsomes. Pharm Res. 2010 Aug; 27(8):1568-83.
    View in: PubMed
    Score: 0.010
  21. Biopharmaceutical and pharmacokinetic characterization of matrine as determined by a sensitive and robust UPLC-MS/MS method. J Pharm Biomed Anal. 2010 Apr 06; 51(5):1120-7.
    View in: PubMed
    Score: 0.009
  22. Structure and concentration changes affect characterization of UGT isoform-specific metabolism of isoflavones. Mol Pharm. 2009 Sep-Oct; 6(5):1466-82.
    View in: PubMed
    Score: 0.009
  23. Determination of osthol and its metabolites in a phase I reaction system and the Caco-2 cell model by HPLC-UV and LC-MS/MS. J Pharm Biomed Anal. 2009 Jul 12; 49(5):1226-32.
    View in: PubMed
    Score: 0.009
  24. Intestinal absorption mechanisms of prenylated flavonoids present in the heat-processed Epimedium koreanum Nakai (Yin Yanghuo). Pharm Res. 2008 Sep; 25(9):2190-9.
    View in: PubMed
    Score: 0.008
  25. Variable isoflavone content of red clover products affects intestinal disposition of biochanin A, formononetin, genistein, and daidzein. J Altern Complement Med. 2008 Apr; 14(3):287-97.
    View in: PubMed
    Score: 0.008
  26. Commentary: bioavailability of flavonoids and polyphenols: call to arms. Mol Pharm. 2007 Nov-Dec; 4(6):803-6.
    View in: PubMed
    Score: 0.008
  27. Disposition of flavonoids via enteric recycling: enzyme stability affects characterization of prunetin glucuronidation across species, organs, and UGT isoforms. Mol Pharm. 2007 Nov-Dec; 4(6):883-94.
    View in: PubMed
    Score: 0.008
  28. Disposition of flavonoids via enteric recycling: determination of the UDP-glucuronosyltransferase isoforms responsible for the metabolism of flavonoids in intact Caco-2 TC7 cells using siRNA. Mol Pharm. 2007 Nov-Dec; 4(6):873-82.
    View in: PubMed
    Score: 0.008
  29. Natural polyphenol disposition via coupled metabolic pathways. Expert Opin Drug Metab Toxicol. 2007 Jun; 3(3):389-406.
    View in: PubMed
    Score: 0.008
  30. Mechanisms responsible for poor oral bioavailability of paeoniflorin: Role of intestinal disposition and interactions with sinomenine. Pharm Res. 2006 Dec; 23(12):2768-80.
    View in: PubMed
    Score: 0.007
  31. Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. Curr Drug Metab. 2005 Oct; 6(5):455-68.
    View in: PubMed
    Score: 0.007
  32. Disposition of formononetin via enteric recycling: metabolism and excretion in mouse intestinal perfusion and Caco-2 cell models. Mol Pharm. 2005 Jul-Aug; 2(4):319-28.
    View in: PubMed
    Score: 0.007
  33. Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos. 2005 Jun; 33(6):785-94.
    View in: PubMed
    Score: 0.007
  34. Quality, labeling accuracy, and cost comparison of purified soy isoflavonoid products. J Altern Complement Med. 2004 Dec; 10(6):1053-60.
    View in: PubMed
    Score: 0.007
  35. Absorption and metabolism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model. Cancer Chemother Pharmacol. 2005 Feb; 55(2):159-69.
    View in: PubMed
    Score: 0.006
  36. Disposition of flavonoids via enteric recycling: enzyme-transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates. J Pharmacol Exp Ther. 2004 Sep; 310(3):1103-13.
    View in: PubMed
    Score: 0.006
  37. Nucleobase- and p-glycoprotein-mediated transport of AG337 in a Caco-2 cell culture model. Mol Pharm. 2004 May-Jun; 1(3):194-200.
    View in: PubMed
    Score: 0.006
  38. Disposition mechanisms of raloxifene in the human intestinal Caco-2 model. J Pharmacol Exp Ther. 2004 Jul; 310(1):376-85.
    View in: PubMed
    Score: 0.006
  39. Metabolism of flavonoids via enteric recycling: mechanistic studies of disposition of apigenin in the Caco-2 cell culture model. J Pharmacol Exp Ther. 2003 Oct; 307(1):314-21.
    View in: PubMed
    Score: 0.006
  40. Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metab Dispos. 2003 Jul; 31(7):924-31.
    View in: PubMed
    Score: 0.006
  41. Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J Pharmacol Exp Ther. 2003 Mar; 304(3):1228-35.
    View in: PubMed
    Score: 0.006
  42. Absorption and metabolism of flavonoids in the caco-2 cell culture model and a perused rat intestinal model. Drug Metab Dispos. 2002 Apr; 30(4):370-7.
    View in: PubMed
    Score: 0.005
  43. P-glycoprotein and bioavailability-implication of polymorphism. Clin Chem Lab Med. 2000 Sep; 38(9):877-81.
    View in: PubMed
    Score: 0.005
  44. Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase. Pharm Res. 1999 Sep; 16(9):1352-9.
    View in: PubMed
    Score: 0.005
  45. Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P4503A4. Pharm Res. 1996 Nov; 13(11):1635-41.
    View in: PubMed
    Score: 0.004
  46. Uptake characteristics of loracarbef and cephalexin in the Caco-2 cell culture model: effects of the proton gradient and possible presence of a distinctive second component. J Pharm Sci. 1996 Jul; 85(7):767-72.
    View in: PubMed
    Score: 0.004
  47. Mechanisms of transport of quinapril in Caco-2 cell monolayers: comparison with cephalexin. Pharm Res. 1995 Aug; 12(8):1120-5.
    View in: PubMed
    Score: 0.003
  48. Peptide transporter function and prolidase activities in Caco-2 cells: a lack of coordinated expression. J Drug Target. 1995; 3(4):291-300.
    View in: PubMed
    Score: 0.003
  49. Mechanism and kinetics of transcellular transport of a new beta-lactam antibiotic loracarbef across an intestinal epithelial membrane model system (Caco-2). Pharm Res. 1994 Oct; 11(10):1405-13.
    View in: PubMed
    Score: 0.003
  50. Mechanisms and kinetics of uptake and efflux of L-methionine in an intestinal epithelial model (Caco-2). J Nutr. 1994 Oct; 124(10):1907-16.
    View in: PubMed
    Score: 0.003
  51. The Caco-2 cell monolayers as an intestinal metabolism model: metabolism of dipeptide Phe-Pro. J Drug Target. 1994; 2(1):79-89.
    View in: PubMed
    Score: 0.003
  52. Comparison of uptake characteristics of thymidine and zidovudine in a human intestinal epithelial model system. J Pharm Sci. 1993 Aug; 82(8):829-33.
    View in: PubMed
    Score: 0.003
  53. A novel local recycling mechanism that enhances enteric bioavailability of flavonoids and prolongs their residence time in the gut. Mol Pharm. 2012 Nov 05; 9(11):3246-58.
    View in: PubMed
    Score: 0.003
  54. Transport of a large neutral amino acid in a human intestinal epithelial cell line (Caco-2): uptake and efflux of phenylalanine. Biochim Biophys Acta. 1992 Jun 29; 1135(3):233-44.
    View in: PubMed
    Score: 0.003
  55. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother. 2012 Sep; 56(9):4625-9.
    View in: PubMed
    Score: 0.003
  56. Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes. Xenobiotica. 2012 Aug; 42(8):808-20.
    View in: PubMed
    Score: 0.003
  57. Sulfation of selected mono-hydroxyflavones by sulfotransferases in vitro: a species and gender comparison. J Pharm Pharmacol. 2011 Jul; 63(7):967-70.
    View in: PubMed
    Score: 0.003
  58. Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein. J Pharm Sci. 2011 Nov; 100(11):5007-17.
    View in: PubMed
    Score: 0.003
  59. Mechanism of L-alpha-methyldopa transport through a monolayer of polarized human intestinal epithelial cells (Caco-2). Pharm Res. 1990 Dec; 7(12):1313-9.
    View in: PubMed
    Score: 0.002
  60. Species and gender differences affect the metabolism of emodin via glucuronidation. AAPS J. 2010 Sep; 12(3):424-36.
    View in: PubMed
    Score: 0.002
  61. Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells. Prostate. 2009 Apr 01; 69(5):494-504.
    View in: PubMed
    Score: 0.002
  62. Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci. 2002 Dec; 91(12):2511-9.
    View in: PubMed
    Score: 0.001
  63. Analysis of drug transport and metabolism in cell monolayer systems that have been modified by cytochrome P4503A4 cDNA-expression. Eur J Pharm Sci. 2000 Nov; 12(1):63-8.
    View in: PubMed
    Score: 0.001
  64. Lispro insulin: adsorption and stability in selected intravenous devices. Diabetes Educ. 1999 Mar-Apr; 25(2):237-45.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.